[Bone metabolism markers and bone histomorphometry in children with chronic renal failure in predialysis period during growth hormone treatment].
The aim of the study was to estimate biochemical bone metabolism markers and bone histomorphometric parameters in children with chronic renal failure (CRF) treated with recombinant human growth hormone (rhGH). Twelve children with CRF aged 2-13.4 years were treated with rhGH 1-1.1 IU/kg per week and alfacalcidol. Bone biopsies were performed before and after 12 months of therapy. An increase in the biochemical markers of bone formation and bone resorption were noted. A statistically significant increase in mineral apposition rate (MAR) was observed in bone histomorphometry. The administration of active vitamin D metabolites enable proper bone mineralization in fast growing children with CRF during rhGH treatment.
Pańczyk-Tomaszewska
M
M
Katedry i Kliniki Pediatrii i Nefrologii Akademii Medycznej w Warszawie.
Ziółkowska
H
H
Debiński
A
A
Sawicki
A
A
Zurowska
A
A
Pietrzyk
J A
JA
Roszkowska-Blaim
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D006435:Renal Dialysis
D000276:Adjuvants, Immunologic; D015415:Biomarkers; D006887:Hydroxycholecalciferols; D013006:Growth Hormone; C008088:alfacalcidol